Journal of Biomedical Research2025，Vol.39Issue(5)：P.452-466,15.DOI:10.7555/JBR.38.20240045
Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in nonsmall cell lung cancer
Liting Lyu 1Xin Hua 2Jiaxin Liu 3Sutong Zhan 4Qianqian Zhang 5Xiao Liang 6Jian Feng 7Yong Song5
作者信息
- 1. Department of Respiratory and Critical Care Medicine,Affiliated Jinling Hospital,Nanjing Medical University,Nanjing,Jiangsu 210002,China Department of Oncology,Affiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China
- 2. Southeast University Medical College,Nanjing,Jiangsu 210003,China
- 3. Department of Respiratory and Critical Care Medicine,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing,Jiangsu 210008,China
- 4. Department of Respiratory and Critical Care Medicine,Nanjing Jinling Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing,Jiangsu 210002,China
- 5. Department of Respiratory and Critical Care Medicine,Affiliated Jinling Hospital,Nanjing Medical University,Nanjing,Jiangsu 210002,China
- 6. Department of Oncology,Affiliated Jiangyin Hospital of Nantong University,Jiangyin,Jiangsu 214400,China
- 7. Department of Pulmonary and Critical Care Medicine,Nantong Key Laboratory of Respiratory Medicine,Affiliated Hospital of Nantong University,Nantong,Jiangsu 226001,China.
- 折叠
摘要
关键词
non-small cell lung cancer/osimertinib/anlotinib/resistance/epithelial-to-mesenchymal transition分类
医药卫生引用本文复制引用
Liting Lyu,Xin Hua,Jiaxin Liu,Sutong Zhan,Qianqian Zhang,Xiao Liang,Jian Feng,Yong Song..Anlotinib reverses osimertinib resistance by inhibiting epithelial-to-mesenchymal transition and angiogenesis in nonsmall cell lung cancer[J].Journal of Biomedical Research,2025,39(5):P.452-466,15.基金项目
supported by the National Natural Science Foundation of China (Grant Nos. 82172728 , 82370096). （Grant Nos. 82172728 , 82370096）
